Compare Stocks: AQST, OCUL, TRLV, and TRVI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.78 +3.7%	$4.45	$2.93 ▼ $7.55	$578.61M	1.48	2.43 million shs	2.45 million shs
OCUL Ocular Therapeutix	$9.99	$9.88	$6.23 ▼ $16.44	$2.19B	0.97	2.06 million shs	2.06 million shs
TRLV Trulieve Cannabis	$11.49 +3.8%	$10.09	$4.62 ▼ $13.28	$2.13B	N/A	2.12 million shs	1.58 million shs
TRVI Trevi Therapeutics	$14.89 -0.4%	$17.44	$8.04 ▼ $20.22	$2.13B	1.04	1.47 million shs	1.65 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+3.69%	-2.05%	+2.58%	-4.97%	-15.70%
OCUL Ocular Therapeutix	0.00%	-6.81%	-9.84%	-1.19%	-17.44%
TRLV Trulieve Cannabis	+3.22%	-0.85%	+4.26%	+33.76%	+1,148,999,900.00%
TRVI Trevi Therapeutics	-0.40%	-6.29%	-17.09%	-14.33%	+82.70%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$4.78 +3.7%	$4.45	$2.93 ▼ $7.55	$578.61M	1.48	2.43 million shs	2.45 million shs
OCUL Ocular Therapeutix	$9.99	$9.88	$6.23 ▼ $16.44	$2.19B	0.97	2.06 million shs	2.06 million shs
TRLV Trulieve Cannabis	$11.49 +3.8%	$10.09	$4.62 ▼ $13.28	$2.13B	N/A	2.12 million shs	1.58 million shs
TRVI Trevi Therapeutics	$14.89 -0.4%	$17.44	$8.04 ▼ $20.22	$2.13B	1.04	1.47 million shs	1.65 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	+3.69%	-2.05%	+2.58%	-4.97%	-15.70%
OCUL Ocular Therapeutix	0.00%	-6.81%	-9.84%	-1.19%	-17.44%
TRLV Trulieve Cannabis	+3.22%	-0.85%	+4.26%	+33.76%	+1,148,999,900.00%
TRVI Trevi Therapeutics	-0.40%	-6.29%	-17.09%	-14.33%	+82.70%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	2.88	Moderate Buy	$9.17	91.77% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	157.76% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	30.55% Upside
TRVI Trevi Therapeutics	3.00	Buy	$27.08	81.89% Upside

Current Analyst Ratings Breakdown

Latest AQST, OCUL, TRLV, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/11/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	AQST Aquestive Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$11.00
8/24/2026	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
8/14/2026	TRVI Trevi Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $28.00
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$23.00
8/7/2026	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $25.00
8/7/2026	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$40.00
8/7/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$44.54M	13.47	N/A	N/A	($0.28) per share	-17.07
OCUL Ocular Therapeutix	$51.95M	42.23	N/A	N/A	$3.07 per share	3.25
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$83.78M	-$0.65	N/A	N/A	N/A	-144.63%	N/A	-52.40%	11/4/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	20.16	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	-$42.76M	-$0.34	N/A	N/A	N/A	N/A	-23.59%	-22.64%	11/12/2026 (Estimated)

Latest AQST, OCUL, TRLV, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	AQST Aquestive Therapeutics	-$0.1050	-$0.18	-$0.0750	-$0.18	$11.42 million	$13.82 million
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	TRVI Trevi Therapeutics	-$0.1095	-$0.11	-$0.0005	-$0.11	N/A	N/A
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	7.19	6.74
OCUL Ocular Therapeutix	0.14	13.10	13.03
TRLV Trulieve Cannabis	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	37.28	37.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
OCUL Ocular Therapeutix	59.21%
TRLV Trulieve Cannabis	N/A
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	6.81%
OCUL Ocular Therapeutix	3.10%
TRLV Trulieve Cannabis	3.79%
TRVI Trevi Therapeutics	15.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	147	125.51 million	116.97 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	N/A
TRVI Trevi Therapeutics	34	142.48 million	120.55 million	Optionable

AQST, OCUL, TRLV, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Recommendation of "Buy" by Brokerages

September 19 at 4:28 AM | marketbeat.com

Michael Thomas Heffernan Sells 39,473 Shares of Trevi Therapeutics (NASDAQ:TRVI) Stock

September 18, 2026 | insidertrades.com

Insider Selling: Trevi Therapeutics (NASDAQ:TRVI) Director Sells 39,473 Shares of Stock

September 17, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Down 6% - Should You Sell?

September 15, 2026 | marketbeat.com

WINTON GROUP Ltd Acquires Shares of 106,852 Trevi Therapeutics, Inc. $TRVI

September 12, 2026 | marketbeat.com

First Light Asset Management LLC Makes New Investment in Trevi Therapeutics, Inc. $TRVI

September 10, 2026 | marketbeat.com

Legal & General Group Plc Takes $1.48 Million Position in Trevi Therapeutics, Inc. $TRVI

September 7, 2026 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

September 5, 2026 | theglobeandmail.com

Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities

September 5, 2026 | theglobeandmail.com

Bank of New York Mellon Corp Invests $5.72 Million in Trevi Therapeutics, Inc. $TRVI

September 5, 2026 | marketbeat.com

Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026

September 3, 2026 | quiverquant.comQ

Trevi Therapeutics to Participate in Upcoming September Conferences

September 3, 2026 | globenewswire.com

Wellington Management Group LLP Boosts Stake in Trevi Therapeutics, Inc. $TRVI

September 2, 2026 | marketbeat.com

Jupiter Topco LLC Purchases New Position in Trevi Therapeutics, Inc. $TRVI

August 29, 2026 | marketbeat.com

Deutsche Bank AG Makes New Investment in Trevi Therapeutics, Inc. $TRVI

August 28, 2026 | marketbeat.com

BlackRock Inc. Acquires New Position in Trevi Therapeutics, Inc. $TRVI

August 28, 2026 | marketbeat.com

Artia Global Partners LP Purchases New Shares in Trevi Therapeutics, Inc. $TRVI

August 27, 2026 | marketbeat.com

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

August 26, 2026 | globenewswire.com

J. Goldman & Co LP Invests $1.51 Million in Trevi Therapeutics, Inc. $TRVI

August 26, 2026 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, OCUL, TRLV, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$4.78 +0.17 (+3.69%)

As of 09/21/2026 04:00 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Ocular Therapeutix NASDAQ:OCUL

$9.99 0.00 (0.00%)

As of 09/21/2026 04:00 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Trulieve Cannabis NYSE:TRLV

$11.49 +0.42 (+3.79%)

As of 09/21/2026 03:58 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

Trevi Therapeutics NASDAQ:TRVI

$14.89 -0.06 (-0.40%)

As of 09/21/2026 04:00 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, OCUL, TRLV, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, OCUL, TRLV, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, OCUL, TRLV, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, OCUL, TRLV, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Ocular Therapeutix NASDAQ:OCUL

Trulieve Cannabis NYSE:TRLV

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQST, OCUL, TRLV, and TRVI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQST, OCUL, TRLV, and TRVI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQST, OCUL, TRLV, and TRVI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, OCUL, TRLV, and TRVI Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

Ocular Therapeutix NASDAQ:OCUL

Trulieve Cannabis NYSE:TRLV

Trevi Therapeutics NASDAQ:TRVI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools